Astria Therapeutics, Inc. financial data

Symbol
ATXS on Nasdaq
Industry
Pharmaceutical Preparations
Location
22 Boston Wharf Road, 10 Th Floor, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
CATABASIS PHARMACEUTICALS INC (to 8/20/2021)
Latest financial report
10-K - Q4 2024 - Mar 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.28K % -9.65%
Debt-to-equity 5.46 % +32.9%
Return On Equity -27.4 % +21.1%
Return On Assets -26 % +22.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 56.4M shares +2.77%
Common Stock, Shares, Outstanding 56.4M shares +37.5%
Entity Public Float 370M USD +32.5%
Common Stock, Value, Issued 57K USD +39%
Weighted Average Number of Shares Outstanding, Basic 56.2M shares +86.4%
Weighted Average Number of Shares Outstanding, Diluted 56.2M shares +86.4%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 34.5M USD +34%
Operating Income (Loss) -112M USD -34.4%
Nonoperating Income (Expense) 17.3M USD +70.6%
Net Income (Loss) Attributable to Parent -94.3M USD -29.3%
Earnings Per Share, Basic -1.68 USD/shares +30.6%
Earnings Per Share, Diluted -1.68 USD/shares +30.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 59.8M USD -65.9%
Cash, Cash Equivalents, and Short-term Investments 328M USD +33.1%
Assets, Current 335M USD +33.4%
Operating Lease, Right-of-Use Asset 5.11M USD +1309%
Other Assets, Noncurrent 2.61M USD -22.5%
Assets 342M USD +34.4%
Accounts Payable, Current 4.32M USD +186%
Employee-related Liabilities, Current 5.08M USD +25.6%
Accrued Liabilities, Current 13.4M USD +38.3%
Liabilities, Current 19.1M USD +65.6%
Operating Lease, Liability, Noncurrent 3.97M USD
Liabilities 23.1M USD +100%
Accumulated Other Comprehensive Income (Loss), Net of Tax 163K USD
Retained Earnings (Accumulated Deficit) -675M USD -16.2%
Stockholders' Equity Attributable to Parent 319M USD +31.3%
Liabilities and Equity 342M USD +34.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -19.1M USD -44.1%
Net Cash Provided by (Used in) Financing Activities 142M USD +283%
Net Cash Provided by (Used in) Investing Activities -126M USD -165%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 56.4M shares +37.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.52M USD -102%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 59.8M USD -66%
Deferred Tax Assets, Valuation Allowance 154M USD +23%
Deferred Tax Assets, Gross 155M USD +24.1%
Operating Lease, Liability 5.35M USD +1527%
Payments to Acquire Property, Plant, and Equipment 5K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -94.1M USD -29.2%
Lessee, Operating Lease, Liability, to be Paid 6.23M USD +1742%
Operating Lease, Liability, Current 1.38M USD +321%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.61M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.45M USD +328%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 872K USD +9589%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.64M USD
Deferred Tax Assets, Operating Loss Carryforwards 93.7M USD +9.23%
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.53M USD
Operating Lease, Payments 1M USD +42.9%
Additional Paid in Capital 899M USD +23.4%
Deferred Tax Assets, Net of Valuation Allowance 1.38M USD +1291%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%